Substrate reduction therapy with Miglustat in pediatric patients with GM1 type 2 gangliosidosis delays neurological involvement: A multicenter experience

Rita Fischetto1 | Valentina Palladino2 | Maria M. Mancardi3 | Thea Giacomini3 | Stefano Palladino4 | Alberto Gaeta4 | Maja Di Rocco5 | Lucia Zampini6 | Giuseppe Lassandro2 | Vito Favia1 | Maria E. Tripaldi2 | Pietro Strisciuglio7 | Alfonso Romano7 | Mariasavina Severino8 | Amelia Morrone9 | Paola Giordano2

Abstract

Background: In GM1 gangliosidosis the lack of function of β-galactosidase results in an accumulation of GM1 ganglioside and related glycoconjugates in visceral organs, and particularly in the central nervous system, leading to severe disability and premature death. In the type 2 form of the disease, early intervention would be important to avoid precocious complications. To date, there are no effective therapeutic options in preventing progressive neurological deterioration. Substrate reduction therapy with Miglustat, a N-alkylated sugar that inhibits the enzyme glucosylceramide synthase, has been proposed for the treatment of several lysosomal storage disorders such as Gaucher type 1 and Niemann Pick Type C diseases. However, data on Miglustat therapy in patients with GM1 gangliosidosis are still scarce.

Methods: We report here the results of Miglustat administration in four Italian children (average age: 55 months, range 20–125) affected by GM1 gangliosidosis type 2 treated in three different Italian pediatric hospitals specialized in metabolic diseases.

Conclusion: This treatment was safe and relatively well tolerated by all patients, with stabilization and/or slowing down of the neurological progression in three subjects.

KEYWORDS

GM1 gangliosidosis, Miglustat, pediatric
GM1 gangliosidosis is an autosomal recessive disorder caused by the deficiency of β-galactosidase (GLB1), a lysosomal hydrolase that removes the terminal β-galactosyl residues from GM1 gangliosides, glycoproteins, and glycosaminoglycans. Lack of β-galactosidase function results in an accumulation of GM1 ganglioside and related glycoconjugates in visceral organs, and particularly in the central nervous system (CNS) (Sandhoff & Harzer, 2013). The incidence of GM1 gangliosidosis is estimated to be 1 in 100,000–200,000 live births, although prevalence widely differs in the world (Brunetti-Pierri & Scaglia, 2008).

β-galactosidase is encoded by GLB1, a gene located on chromosome 3p21.33 (Yamamoto et al., 1990). To date, more than 200 mutations have been identified (HGMD professional database 2015.3; https://portal.biobase-international.com/cgibin/portal/login.cgi), differing in the residual enzyme activity that inversely correlates with the clinical severity (Suzuki, Nakamura, & Fukuoka, 1978). Despite the large genetic variability, currently, three main clinical forms have been identified: type 1 (infantile), type 2 (late infantile and juvenile), and type 3 (adult). GM1 gangliosidosis type 1 is characterized by early psychomotor deterioration, visceromegaly, macular cherry-red spot, skeletal deformities, and death within the first 2 years of life (Suzuki & Oshima, 1993). Type 2 form presents with slowly progressive neurological signs as early locomotor problems, strabismus, muscle weakness, seizures, recurrent bronchopneumonia, and less severe dysmorphisms and skeletal involvement than in type 1. GM1 gangliosidosis type 2 can be divided into a late infantile and a juvenile form. In the late infantile form death occurs within adolescence while patients with the juvenile form can survive longer, with great individual clinical variability (Regier & Tifft, 2013). The adult form (type 3) is characterized by a less severe course and late onset, usually in juvenile age (Cox, 2015; Jarnes Utz et al., 2017; Regier, Proia, D’Azzo, & Tifft, 2016). Data on neuroimaging findings in the different forms of GM1 gangliosidosis are scarce; the reported patterns are nonspecific, including diffuse atrophy and white matter abnormalities (Chen et al., 1998; De Grandis, Di Rocco, Pessagno, Veneselli, & Rossi, 2009; Di Rocco et al., 2005; Gururaj et al., 2005). Type 1 may also present with delayed myelination and hyposignal on T2-weighted images in the thalami, while type 2 may be associated with T2 hypointensity in the globi pallidi, and type 3 shows T2 hyperintensity within the putamina (Chen et al., 1998; De Grandis et al., 2009; Di Rocco et al., 2005; Erol, Alehan, Pourbagher, Canan, & Vefa, 2006; Gururaj et al., 2005).

To date, there are no effective drugs for the management of GM1 gangliosidosis that is mainly based on palliative treatments. Especially in the infantile and juvenile forms of GM1 gangliosidosis, early intervention would be important to avoid severe disability and premature death. However, the failure to access glycolipid storage products in CNS cells during critical developmental periods and the absence of clinical markers to evaluate treatment efficacy have hindered progress in developing effective therapies (Jarnes Utz et al., 2017).

Recently, the application of a substrate reduction therapy (SRT) has been evaluated in several lysosomal storage disorders (Hollak & Wijburg, 2014; Parenti, Andria, & Valenzano, 2015). The rationale of SRT is based on the use of synthesis inhibitors of substrates accumulated in lysosomes using specific iminosugars (Jeyakumar, Butters, Dwek, & Platt, 2002). NB-DNJ (Miglustat, Zavesca®) is a N-alkylated sugar that is a reversible competitive inhibitor of the glucosylceramide synthase, an enzyme catalyzing the first committed step in the synthesis of lacto- and globo-series glycolipids (Platt, Neises, Dwek, & Butters, 1994). The ability of Miglustat to cross the blood–brain barrier blocking glycolipid storage synthesis has opened new interesting options for the treatment of multiple lysosomal storage disorders, especially those with CNS involvement, such as Gaucher and Niemann Pick type C diseases (Cox et al., 2000; Ficicioglu, 2008; Patterson, Vecchio, Prady, Abel, & Wraith, 2007). Miglustat has also been proposed for treatment of other sphingolipidoses, such as GM1 gangliosidosis. Indeed, GM1 gangliosidosis mouse models demonstrated Miglustat effectiveness in reducing brain GM1 ganglioside content (Kasperzyk et al., 2004; Treiber, Morand, & Clozel, 2007). Data on Miglustat efficacy in patients with GM1 gangliosidosis are scarce but promising, as reported in a few pediatric and adult patients affected by type 1 and 2 forms (Deodato et al., 2017; Garzone et al., 2013; Tifft, Adams, & Morgan, 2007).

Here, we describe the clinical course and adverse effects of Miglustat therapy in four pediatric patients with GM1 gangliosidosis type 2.

2 | MATERIALS AND METHODS

After obtaining informed consent and approval from the local ethics committees, we reviewed the clinical and neuroradiological data of four patients with GM1 gangliosidosis treated in three different Italian pediatric hospitals specialized in metabolic diseases. The decision to initiate treatment was based on: (a) good safety profile of Miglustat, (b) good clinical results in other lysosomal storage diseases, and (c) promising preclinical data on GM1 mouse models. Miglustat was dosed according to guidelines for pediatric patients (younger than 12 years) affected by Niemann Pick type C disease. The drug was melted in water to facilitate the assumption and the dosage was progressively increased according to body surface area. Data on drug tolerance and compliance were collected from the mothers with follow-up calls or during...
| Patient | Age at onset of symptoms | Age at Miglustat initiation | Age at last follow-up during Miglustat therapy | Symptoms and signs Before Miglustat therapy | Symptoms and signs After Miglustat therapy | Neurological evaluation Before Miglustat therapy | Neurological evaluation After Miglustat therapy |
|---------|------------------------|-----------------------------|-----------------------------------------------|---------------------------------------------|---------------------------------------------|-----------------------------------------------|-----------------------------------------------|
| 1       | 11 months              | 20 months                   | 5 years                                       | • Thoracolumbar kyphosis and vertebral beaking (D11 to L4) at X-ray | • Significant improvement of the thoracic hyperkyphosis and stable appearance of the vertebral anomalies | • Normal neurological assessment | WPPSI-III: mild worsening in fine motor skills and language |
|         |                        |                             |                                               | • Abdominal cystic lymphangioma               | • Normal WPPSI-III in verbal and performance IQ scores | • Normal WPPSI-III in verbal and performance IQ scores | • Normal WPPSI-III in verbal and performance IQ scores |
| 2       | 5 years                | 10 years and 5 months       | 16 years                                      | • Developmental regression                   | Stable                                       | Stable motor and cognitive impairment       | Stable motor and cognitive impairment       |
|         |                        |                             |                                               | • Attention deficit                          | • Severe dysarthria                          | • Severe cognitive impairment (IQ of 34 at WISC-III Scale) and EDSS score of 7.5 | • Severe cognitive impairment (IQ of 34 at WISC-III Scale) and EDSS score of 7.5 |
|         |                        |                             |                                               | • Dysarthria                                 | • Attention deficit                          | • Moderate intellectual disability          | • Moderate intellectual disability          |
|         |                        |                             |                                               | • Attention deficit                          | • Mild hypotonia                             | • Clumsiness                               | • Clumsiness                               |
|         |                        |                             |                                               | • Dysarthria                                 | • Brisk reflex with mild bilateral clonus    | • Dysarthria                               | • Dysarthria                               |
|         |                        |                             |                                               | • Extrapyramidal symptoms                    | • Awkwardness                               | • Significant hyperkinesia                 | • Significant hyperkinesia                 |
|         |                        |                             |                                               | • Atypical absences                          | • Bradykinesia with freezing                | • Attention deficit                        | • Attention deficit                        |
|         |                        |                             |                                               | • Diffuse platyspondyly with mild anterior wedging of the lumbar vertebrae at Spinal MRI and X-ray | • Gait ataxia                               | • Behavioral problems with heteromagnessivity | • Behavioral problems with heteromagnessivity |
|         |                        |                             |                                               |                                               | • Severe cognitive impairment (IQ of 34 at WISC-III Scale) and EDSS score of 7.5 | • Psychomotor agitation outbursts           | • Psychomotor agitation outbursts           |
|         |                        |                             |                                               |                                               |                                               | • EDSS score of 5.                         | • EDSS score of 5.                         |

(Continues)
### TABLE 1 (Continued)

| Patient | Age at onset of symptoms | Age at Miglustat initiation | Age at last follow-up during Miglustat therapy | Symptoms and signs Before Miglustat therapy | Neurological evaluation Before Miglustat therapy | Symptoms and signs After Miglustat therapy | Neurological evaluation After Miglustat therapy |
|---------|--------------------------|-----------------------------|-----------------------------------------------|---------------------------------------------|-----------------------------------------------|------------------------------------------|-----------------------------------------------|
| 4       | 18 months                | 2 years and 9 months        | 6 years and 7 months                          | • Hypotonia                                  | • Total regression of language                 | • Hypotonia                                | • Total regression of language               |
|         |                          |                             |                                               | Delayed psychomotor development             | Pyramidal and extrapyramidal signs            | Delayed psychomotor development           | Pyramidal and extrapyramidal signs          |
|         |                          |                             |                                               | Steppage gait                                | Seizures                                      | Steppage gait                             | Seizures                                      |
|         |                          |                             |                                               | Slightly coarse facies                       | Severe intellectual disability               |                                          | Severe intellectual disability              |
|         |                          |                             |                                               | (downturned corners of the mouth, convergent | Total gross and fine motor regression        |                                          | Total gross and fine motor regression       |
|         |                          |                             |                                               | strabismus of the left eye, and open bite    |                                               |                                          |                                               |
|         |                          |                             |                                               | with sialorrhea                               |                                               |                                          |                                               |

#### 2.1 Patient 1

Patient #1 was born at term after an uneventful pregnancy by spontaneous delivery. He was the first child of a healthy nonconsanguineous couple, with no contributory family history. Normal growth and neurodevelopment milestones were referred until the age of 11 months. At this time, he was referred to the orthopedist for thoracolumbar kyphosis. The first clinical evaluation did not reveal any dysmorphological signs. Spine X-Ray showed anterior vertebral beaking from D1 to L4, more evident in L1 and L2, associated with marked thoracic kyphosis.

Clinical assessment every 3 months. All patients were followed up at regular intervals by a multidisciplinary team and the development of side effects was monitored. Symptoms and signs of side effects were summarized in Table 1.

#### Patient 1

**TABLE 1**

| Age at onset of symptoms | Age at Miglustat initiation | Age at last follow-up during Miglustat therapy | Symptoms and signs Before Miglustat therapy | Neurological evaluation Before Miglustat therapy | Symptoms and signs After Miglustat therapy | Neurological evaluation After Miglustat therapy |
|--------------------------|-----------------------------|-----------------------------------------------|---------------------------------------------|-----------------------------------------------|------------------------------------------|-----------------------------------------------|
|                          |                             |                                               |                                            |                                               |                                          |                                               |
| 4                        | 18 months                   | 2 years and 9 months                         | • Hypotonia                                 | • Total regression of language                | • Hypotonia                               | • Total regression of language               |
|                          |                             |                                               | Delayed psychomotor development           | Pyramidal and extrapyramidal signs            | Delayed psychomotor development           | Pyramidal and extrapyramidal signs          |
|                          |                             |                                               | Steppage gait                               | Seizures                                      | Steppage gait                             | Seizures                                      |
|                          |                             |                                               | Slightly coarse facies                      | Severe intellectual disability               |                                          | Severe intellectual disability              |
|                          |                             |                                               | (downturned corners of the mouth, convergent strabismus of the left eye, and open bite with sialorrhea) | Total gross and fine motor regression        |                                          | Total gross and fine motor regression       |
appearance of the vertebral anomalies. Follow-up brain MRI scans at 4 and 5 years of age did not reveal any abnormality. Cognitive assessment using WPPSI-III performed at 5 years of age showed mild worsening in fine motor skills and language. Routine blood tests were normal, except for mild and transient increase in alanine amino transpherase (ALT) levels.

2.2 | Patient 2

Patient #2 is the first child of healthy nonconsanguineous parents with negative family history. She was born at term after an uneventful pregnancy. She showed a normal psychomotor development until the age of 5 years when she presented with developmental regression associated with attention deficit, dysarthria, and extrapyramidal symptoms. She came to our attention at the age of 9 years when she developed atypical absences with generalized sharp waves (3 Hz) followed by slow waves lasting 20–12′ at EEG, and she started antiepileptic therapy with lamotrigine. Neurological examination showed severe dysarthria, mild hypotonia, brisk reflex with mild bilateral clonus, awkwardness, bradykinesia with freezing, and gait ataxia; she could not walk without assistance. Neuropsychological evaluation showed severe cognitive impairment (IQ of 34 at WISC-III Scale) and EDSS score of 7.5. Brain MRI performed at 8 years of age revealed mild cerebral and cerebellar atrophy, white matter signal alterations consistent with lack of myelin, dysmyelination, and reduced thalamic volume (Figure 2D–F). Brain MR spectroscopy was normal. Spinal MRI and X-ray showed diffuse platyspondyly with mild anterior wedging of the lumbar vertebrae (Figure 1b,c). Routine blood tests were normal, as well as genetic exams including cytogenetic studies, Array – Comparative Genomic Hybridization (Array – CGH), and analysis of subtelomeric regions and MECP2 gene.

Metabolic exams, including blood chromatography of the amino acids, organic acidurias, mucopolysaccharidosis (MPS) urinary screening, plasma chitotriosidase, and fucosidase, mannosidase, were normal while the activity of β-galactosidase was reduced in lymphocytes (16.2 nM mg⁻¹ h⁻¹; normal values 100–600 nM mg⁻¹ h⁻¹) as well as in cultured skin fibroblasts, leading to the diagnosis of GM1 gangliosidosis. The genetic analysis revealed compound heterozygous mutations in GLB1 in c.602G>A p.(Arg201His) and the novel c.247dup1 p.(Tyr83Leu fsx8).

At the age of 10 years and 5 months, the clinical picture and neurological examination were stable. Brain MRI showed mild progression of cerebral atrophy with enlargement of the lateral ventricles (Figure 2D′–F′). Therapy with Miglustat was started (age 10 years and 5 months) at the dosage of 100 mg three times a day, gradually increased to 200 mg three times a day. She initially presented occasional diarrhea and mild abdominal pain, spontaneously improving in the following weeks. In the first 4 months of therapy, her

![FIGURE 1](image) Spinal X-ray and MRI features of the patients. (a) Spinal X-ray, lateral view, of patient #1 performed at 6 years showing platyspondyly with anterior vertebral beaking from D11 to L4, more evident in L1 and L2 (arrows). (b) Spinal MRI, T2-weighted sagittal image, and (c) Spinal X-ray, lateral view, of patient #2 performed at 15 years of age demonstrates diffuse platyspondyly with mild anterior wedging of the lumbar vertebrae. (d) Spinal X-ray, lateral view, of patient #3 performed at 9 years of age reveals diffuse platyspondyly with mild anterior wedging of the lumbar vertebrae, more evident in L3 (arrow)
body weight decreased from 42.6 to 38.9 kg (BMI from 24.8 to 21.9). Subsequently, in the following 6 years, the BMI was quite stable between 21.1 and 22.3. She has now been on a stable dosage of 600 mg/day for 1 year with good compliance and without relevant adverse events. At last follow-up, at the age of 16 years, neurological examination showed stable motor and cognitive impairment. Brain MRI revealed further progression of mild cortical atrophy and T2 hypointensity at the level of the globi pallidi, substantia nigra, red nuclei, and cerebellar dentate nuclei, associated with thickening of the skull bones (Figure 2D″–F″).

2.3 | Patient 3

Patient #3 is the younger brother of Patient #2. He was born at term after an uneventful pregnancy. He was asymptomatic when GM1 gangliosidosis were diagnosed at the age of 3 years, and he harbored the same compound mutations of his sister. Treatment with Miglustat was started at the age of 3 years and 8 months but was stopped after a week for the appearance of severe hyporexia. Four months later, the treatment was reinitiated at the dosage of 70 mg/twice daily and gradually increased up to 300 mg/day (subdivided into 3 doses). Up to date, he has been on a stable dosage for 3 years with good compliance and insignificant side effects such as occasional abdominal pain with diarrhea. At the age of 5 years, he started to develop dysarthria and attention deficit.

Brain MRI with MR spectroscopy performed at 6 years and 2 months was normal (Figure 2G–I). Spinal X-ray revealed diffuse platyspondyly with anterior wedging of the lumbar vertebrae, especially of L3 (Figure 1d). At 10 years of age, he presented epileptic alterations at EEG during sleep, without evident clinical seizures and was treated with therapy with topiramate. Neurological examination revealed moderate intellectual disability, clumsiness, dysarthria, significative hyperkinesia,
attention deficit, behavioral problems with heteroaggressivity, and psychomotor agitation outbursts. His EDSS score was 5. At last follow-up, performed at 10 years and 5 months of age, neurological examination revealed a stable clinical course.

### 2.4 Patient 4

Patient #4 was born at term after an uneventful pregnancy by spontaneous delivery. At the age of 18 months, he presented with hypotonia, delayed psychomotor development, and a steppage gait characterized by widened base of support and retropulsion of the pelvis. He had slightly coarse facies with downturned corners of the mouth, convergent strabismus of the left eye, and open bite with sialorrhea. Abdominal ultrasound and metabolic screening tests were normal. Brain MRI performed at 2 years of age revealed white matter signal alterations consistent with lack of myelin and dysmyelination in the posterior limbs of internal capsules and pons, mild subarachnoid spaces enlargement, and reduced thalamic volume (Figure 2J–L). At the age of 2 years and 4 months, GM1 gangliosidosis was diagnosed by the β-galactosidase enzymatic assay and GLB1 gene molecular analysis, which highlighted the presence in heterozygosis of the c.572G>A (p. Ser191Asn) and c.1445G>A (p. Arg482Hys) mutations. The boy started therapy with Miglustat at the age of 2 years and 9 months, at the dosage of 200 mg (subdivided into two doses).

At the age of 3 years and 2 months, the patient was again hospitalized for night cry, asthenia, and pain. The abdomen ultrasound was normal, while a barium X-ray examination showed gastrointestinal reflux and therapy was initiated with esomeprazole. The neurological exam showed total regression of language, associated with pyramidal and extrapyramidal signs.

At the age of 3 years and 7 months, frequent daily seizures appeared, lasting few seconds and characterized by pathological eyes rolling and staring. An EEG showed high-voltage slow waves and spike waves complexes on the right derivations. He began therapy with levetiracetam at the dosage of 400 mg/die with clinical improvement.

When he was 6 years old, he was hospitalized because of significant weight loss, dehydration, sickness, and vomiting. Oral feeding was strongly compromised. A percutaneous gastrostomy was placed. Seven months later, therapy with Miglustat was also suspended. Last clinical follow-up at 7 years of age revealed severe intellectual disability and total gross and fine motor regression. He depended on his parents for daily survival.

### 3 DISCUSSION

We present our experience of Miglustat administration in four children affected by GM1 gangliosidosis type 2. In GM1 gangliosidosis type 2, the accumulation of GM1 ganglioside in the CNS begins in the early stages of development. Therefore, it has been hypothesized that the progression of the disease could only be avoided with early diagnosis and intervention (Del Vecchio et al., 2008; Jarnes Utz et al., 2017).

Some therapeutic strategies have been implemented in animal models, such as bone marrow transplantation (Sano, Tessitore, Ingrassia, & d’Azzo, 2005), intracranial transplant of neuronal stem cells (Sawada et al., 2009), SRT (Elliot-Smith et al., 2008; Kasperzyk et al., 2004; Suzuki et al., 2007), gene therapies (Baek et al., 2010), and enzyme replacement therapy (Condori et al., 2016). Additionally, a recent study demonstrated that the intracerebroventricular administration of recombinant human β-galactosidase in a mouse model of GM1 gangliosidosis reduced brain levels of ganglioside and oligosaccharide substrates (Chen et al., 2019).

In human patients, several interventions have been undertaken to mitigate the relentless progression of disease (Regier et al., 2016). However, the failure to access glycolipid storage products in CNS during critical developmental periods and the absence of clinical markers to evaluate treatment efficacy have hindered progress in developing effective therapies (Jarnes Utz et al., 2017).

Substrate reduction therapy with oral administration of the iminosugar NB-DNJ has been demonstrated to be effective in crossing the blood–brain barrier and blocking glycolipid storage synthesis (Kasperzyk et al., 2004; Treiber et al., 2007), thus revealing a potential therapeutic role in lysosomal storage disorders with neurological involvement (Platt et al., 1994). In particular, Miglustat has been approved in Europe and the United States for the treatment of patients with type 1 Gaucher disease with mild-to-moderate clinical manifestations for whom intravenous enzyme replacement therapy is not an option (Cox et al., 2000; Ficicioglu, 2008). Subsequently, Miglustat has also been approved for treating progressive neurologic manifestations in children and adults with Niemann Pick disease type C (Patterson et al., 2007).

The mechanism of Miglustat action has not been completely clarified yet. The efficacy of NB-DNJ is related to its ability to cross the blood–brain barrier, inhibit the synthesis of storage products, and stabilize the enzyme with an enhancement of the catalytic residual activity (Alfonso et al., 2005; Kuter et al., 2013). Furthermore, several studies have proved the potential role of Miglustat administration in the regulation of the abnormal CNS inflammatory response observed in GM1 gangliosidosis (Jeyakumar et al., 2003), reducing levels of proinflammatory cytokines such as tumor necrosis factor-α (TNF-α) and interleukin-1 beta (IL1-β) (Jeyakumar et al., 2001; Masciullo et al., 2010; Santoro et al., 2013).

Despite the demonstrated effectiveness of Miglustat in other storage disorders, its use in GM1 gangliosidosis type 2 has been reported only in a few patients. In 2007, Tifft et al. (2007) reported that Miglustat administration improved
neurological functions in two patients with juvenile GM1 gangliosidosis. Recently, Deodato et al. (2017) described similar neurological improvement in the juvenile form of the disease. In our patients, we observed stabilization and/or slowing down of the neurological progression in three of four patients. Of note, the administration of Miglustat was started few months after the genetic confirmation. In particular, patients #1 and #3 received an early diagnosis of GM1 gangliosidosis type 2 and the treatment was started within the fourth year of age, before the onset of neurological symptoms. In patient #1, early treatment limited the disease progression until 5 years of age, when minor motor problems were noticed. Moreover, the improvement of the kyphosis without other novel skeletal manifestations and the absence of neuromaging abnormalities were indicative of substantial stabilization of the clinical course due to the treatment. In patient #3, who was asymptomatic at the beginning of therapy, we noted a very slow progression of symptomatology, appeared at the age of 5 years and evident since the age of 8 years, thus suggesting a possible role of Miglustat in slowing down the neurological deterioration.

Patient #2 started the therapy rather late in the course of the disease, at the age of 10 years, when neurological symptoms and MRI alterations were already present. Surprisingly, in this case, we observed a stable motor and cognitive impairment for the following 5 years, while brain MRI showed only a minimal progression of the cerebral atrophy. On the other hand, Miglustat therapy was insufficient to avoid worsening of the clinical course in patient #4, who presented with a severe neurological phenotype since the first months of life.

Consensus guidelines for clinical management of children with Niemann Pick type C recommend close clinical monitoring after the initiation of Miglustat therapy (NP-C Guidelines Working Group, 2009). However, several studies have proved that Miglustat is safe and generally well tolerated, with minor and often transient adverse effects, such as tremor and gastrointestinal disturbances (Belmatoug et al., 2011). In particular, gastrointestinal problems, including diarrhea, abdominal pain, nausea, and weight loss, are mainly dose-related and limited to the initial phase of the treatment. The mechanism is most likely the inhibition of intestinal disaccharidases leading to reduced absorption of dietary disaccharides and increase in undigested intraluminal oligosaccharides creating an osmotic gradient with the influx of water and electrolytes in the gastrointestinal tract. Subsequent colonic bacterial fermentation reduces colonic supply and triggers flatulence, abdominal distension, pain, and nausea. Of note, these symptoms generally disappear or decrease with dose escalation or discontinued administrations in association with a low-carbohydrate/lactose diet and probiotic administration (Cox, 2015; Patterson et al., 2007). In this series, two patients presented minor gastrointestinal problems. In particular, patient #2 developed transient diarrhea and abdominal pain, while patient #3 presented severe hyporexia that subsided after brief treatment suspension and did not reappear after Miglustat reintroduction at lower and fractionated doses while occasional abdominal pain with diarrhea persisted. Interestingly, in patient #1, Miglustat therapy was started after 2 months of a preliminary diet based on lactose-free products and daily assumption of probiotic Saccharomyces Boulardii, thus avoiding gastrointestinal symptoms (carbohydrates were preserved in order to maintain an adequate nutrition).

In conclusion, our findings suggest that Miglustat is relatively well tolerated in children with GM1 type 2 gangliosidosis and seems more effective if used to slow down, rather than treat, both visceral and neurological manifestation, as in Niemann Pick type C pediatric patients (Di Rocco, Dardis, Madeo, Barone, & Fiumara, 2012). The rarity of GM1 gangliosidosis type 2 disease, fast clinical progression, and short lifespan make studies on clinical surveillance and therapeutic efficacy tough, as effective interventions are only possible before irreversible damage occurs. Since definitive conclusions cannot be drawn from small case series, further studies on larger number of patients and with longer follow-up duration are needed to evaluate of the long-term therapeutic effects of Miglustat in GM1 type II gangliosidosis.

ACKNOWLEDGMENTS
All authors contributed equally to the study design and performance.

CONFLICT OF INTEREST
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

AUTHOR CONTRIBUTIONS
All authors listed have made a substantial, direct and intellectual contribution to the work, and approved it for publication.

DATA AVAILABILITY STATEMENT
The data supporting the findings of the article can be requested to the authors at the following.

ORCID
Valentina Palladino https://orcid.org/0000-0002-3976-6463
Maja Di Rocco https://orcid.org/0000-0001-9677-880X
Amelia Morrone https://orcid.org/0000-0003-2890-8179

REFERENCES
Alfonso, P., Pamplín, S., Estrada, J., Rodríguez-Rey, J. C., Giraldo, P., Sancho, J., & Pocoví, M. (2005). Miglustat (NB-DNJ) works as a chaperone for mutated acid beta-glucosidase in cells transfected with several Gaucher disease mutations. Blood Cells, Molecules & Diseases, 35, 268–276. https://doi.org/10.1016/j.bcmd.2005.05.007
Niemann-Pick disease type C. *Molecular Genetics and Metabolism*, 98, 152–165. https://doi.org/10.1016/j.ymgme.2012.03.012

Parenti, G., Andria, G., & Valenzano, K. J. (2015). Pharmacological chaperone therapy: Preclinical development, clinical translation, and prospects for the treatment of lysosomal storage disorders. *Molecular Therapy*, 23, 1138–1148. https://doi.org/10.1038/mt.2015.62

Patterson, M. C., Vecchio, D., Prady, H., Abel, L., & Wraith, J. E. (2007). Miglustat for treatment of Niemann-Pick C disease: A randomised controlled study. *The Lancet Neurology*, 6, 765–772. https://doi.org/10.1016/S1474-4422(07)70194-1

Platt, F. M., Neises, G. R., Dwek, R. A., & Butters, T. D. (1994). N-butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis. *The Journal of Biological Chemistry*, 269, 8362–8365.

Regier, D. S., Proia, R. L., D’Azzo, A., & Tifft, C. J. (2016). The GM1 and GM2 Gangliosidoses: Natural history and progress toward therapy. *Pediatric Endocrinology Review: PER*, 13, 663–673.

Regier, D. S., & Tifft, C. J. (2013). GLB1-related disorders. In M. P. Adam, H. H. Ardinger, S. E. Wallace, L. J. H. Bean, K. Stephens, A. Amemiya, (Eds.), *GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2015. Retrieved from http://www.ncbi.nlm.nih.gov/books/NBK164500/

Sandhoff, K., & Harzer, K. (2013). Gangliosides and gangliosidoses: Principles of molecular and metabolite pathogenesis. *The Journal of Neuroscience*, 33, 10195–10208. https://doi.org/10.1523/JNEURSCI.0822-13.2013

Sanz, R., Tessitore, A., Ingrassia, A., & d’Azzo, A. (2005). Chemokine-induced recruitment of genetically modified bone marrow cells into the CNS of GM1-gangliosidosis mice corrects neuronal pathology. *Blood*, 106, 2259–2268. https://doi.org/10.1182/blood-2005-03-1189

Santoro, N., Colombini, A., Silvestri, D., Grassi, M., Giordano, P., Parasole, R., … Rizzari, C. (2013). Screening for coagulopathy and identification of children with acute lymphoblastic leukemia at a higher risk of symptomatic venous thrombosis: An AIEOP experience. *Journal of Pediatric hematology/oncology*, 35, 348–355. https://doi.org/10.1097/MPH.0b013e318288dc614

Sawada, T., Tanaka, A., Higaki, K., Takamura, A., Nanba, E., Seto, T., … Yamano, T. (2009). Intracerebral cell transplantation therapy for murine GM1 gangliosidosis. *Brain & Development*, 31, 717–724. https://doi.org/10.1016/j.braindev.2008.11.004

Suzuki, Y., Ichinomiya, S., Kuwasawa, M., Ohkubo, M., Watanabe, H., Iwasaki, H., … Brady, R. O. (2007). Chemical chaperone therapy: Clinical effect in murine G(M1)-gangliosidosis. *Annals of Neurology*, 62, 671–675. https://doi.org/10.1002/ana.21284

Suzuki, Y., Nakamura, N., & Fukuoka, K. (1978). GM1-gangliosidosis: Accumulation of ganglioside GM1 in cultured skin fibroblasts and correlation with clinical types. *Human Genetics*, 43, 127–131. https://doi.org/10.1007/bf00293589

Suzuki, Y., & Oshima, A. (1993). A beta-galactosidase gene mutation identified in both Morquio B disease and infantile GM1 gangliosidosis. *Human Genetics*, 91, 407. https://doi.org/10.1007/bf00217370

Tifft, C., Adams, T. R., & Morgan, C. P. (2007). Miglustat improves function in patients with juvenile GM1 gangliosidosis. *Molecular Genetics and Metabolism*, 92(4), 24.

Treiber, A., Morand, O., & Clozel, M. (2007). The pharmacokinetics and tissue distribution of the glucosylceramide synthase inhibitor miglustat in the rat. *Xenobiotica*, 37, 298–314. https://doi.org/10.1080/00498250601094543

Yamamoto, Y., Hake, C. A., Martin, B. M., Kretz, K. A., Ahern-Rindell, A. J., Naylor, S. R., … O’Brien, J. S. (1990). Isolation, characterization, and mapping of a human acid beta-galactosidase cDNA. *DNA and Cell Biology*, 9, 119–127. https://doi.org/10.1089/dna.1990.9.119

How to cite this article: Fischetto R, Palladino V, Mancardi MM, et al. Substrate reduction therapy with Miglustat in pediatric patients with GM1 type 2 gangliosidosis delays neurological involvement: A multicenter experience. *Mol Genet Genomic Med*. 2020;00:e1371. https://doi.org/10.1002/mgg3.1371